Japan approves another biosimilar G-CSF

Nippon Kayaku Co. Ltd. (Tokyo:4272) said Japan approved Filgrastim NK, a biosimilar of granulocyte colony-stimulating factor (G-CSF), to treat chemotherapy-induced neutropenia (CIN). The product is partnered with Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), which was unchanged at $37.25 on Monday. ...